AD
2024-06-22 20:47:43 +0300

HC Wainwright Believes This Cancer-Focused Stock Is Undervalued At $550M

Logo Benzinga
Benzinga
By Vandana Singh
  • HC Wainwright initiated coverage ofCelularity IncCELU with a Buy rating and a price target of $15.
  • HC Wainwright believes Celularity's current valuation of approximately $550 million is undervalued considering the upside potential of the company's platform and provides an attractive entry point for long-term investors.
  • The analyst wrote that the company had developed the IMPACT platform to manufacture multiple types of cell therapies, such as NK cells and CAR-T cells, from placental cells by taking advantage of their superior stemness and safety profile.
  • The company is assessing CYNK-001, an unmodified NK cell therapy for acute myeloid leukemia (AML) and glioblastoma multiforme (GBM).
  • A clinical update from the study's r/r AML and MRD cohorts in 2H22 and 1Q23, respectively. The company has also initiated a Phase 1/2 study with CYNK-001 for recurrent GBM, with initial data expected in 2H 2022.
  • If successful, the analyst anticipates Phase 2 proof of concept study to start in early 2023.
  • The analyst expects these cell therapy products to enter the market in 2025 and grow to nearly $1.4 billion on a risk-adjusted basis by 2030, with almost $300 million from CYNK-001 and $1.1 billion from CyCART-19.
  • Price Action:CELU shares are down 0.79% at $3.75 during the market session on the last check Wednesday.
AD
AD

2022 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

Continue read on benzinga.com

AD
Logo Benzinga
Business / FinanceBy Globe Newswire2024-07-13 13:05:24 +0300
New York, July 13, 2024 (GLOBE NEWSWIRE) -- Reportlinker.com announces the release of the report Natural Killer (NK) Cell Therapeutics Market - A Global and...

Logo Benzinga
MarketsBy Pr Newswire2024-06-28 09:16:00 +0300
STOCKHOLM, June 28, 2024 /PRNewswire/ -- XNK Therapeutics AB (XNK) today announced it is initiating a program targeting urothelial cancer, the most common...

Logo Benzinga
MarketsBy Vandana Singh2024-07-06 18:38:58 +0300
Ayala Pharmaceuticals Inc AYALA reported data from Part A of its Phase 2 (RINGSIDE) trial evaluating AL102 in patients with desmoid tumors on Tuesday. At 16...

Logo Benzinga
MarketsBy Ragothaman Srinivasan2024-06-29 15:53:48 +0300
The U.S. Food and Drug Administration (FDA) has granted orphan drug designation to ALX Oncology Holdings ALXO Evorpacept for the treatment of patients with...

Logo Benzinga
MarketsBy Vandana Singh2024-07-13 21:45:54 +0300
HC Wainwright downgraded Humanigen Inc HGEN to Neutral from Buy and removed the price target based on the removal of COVID-19 from lenzilumab projections and...

Logo Nasdaq
MarketsBy Rtt News2024-06-23 16:02:00 +0300
(RTTNews) - Biopharmaceutical company CNS Pharmaceuticals, Inc. (CNSP) announced Thursday that it has received approval from the U.S. Food and Drug...

Logo Benzinga
MarketsBy Vandana Singh2024-07-01 22:39:36 +0300
HC Wainwright initiated coverage on NRx Pharmaceuticals Inc NRXP with a Buying rating and a price target of $2. Earlier today, the FDA declined to issue an...

Logo Benzinga
Business / FinanceBy Pr Newswire2024-06-16 03:00:00 +0300
PHILADELPHIA and ST. LOUIS, MO and SAN DIEGO, June 15, 2024 /PRNewswire/ --WuXi Advanced Therapies (WuXi ATU), a global Contract Testing, Development and...

Logo Benzinga
Business / FinanceBy Pr Newswire2024-07-13 11:38:00 +0300
Glioblastoma multiforme is one of the most complex, deadly and treatment-resistant cancer with a 5-year survival rate of 6.8% and an average length of...

Logo Benzinga
Business / FinanceBy Pr Newswire2024-07-13 15:05:00 +0300
The company is currently enrolling patients in a multi-center Phase 1 clinical trial for the treatment of recurrent glioblastoma (GBM) OAKDALE, Minn., July...

Logo Benzinga
MarketsBy Vandana Singh2024-06-23 22:03:30 +0300
Last week, Addex Therapeutics Ltd ADXN terminated the Phase 2b/3 study evaluating dipraglurant as a potential treatment for dyskinesia associated with...

Logo Benzinga
Business / FinanceBy Pr Newswire2024-06-20 07:00:00 +0300
EPALINGES, Switzerland and MONTPELLIER, France, June 20, 2024 /CNW/ --Onward Therapeutics SA (Onward Therapeutics) and Emercell SAS (Emercell) announced...

Logo Benzinga
MarketsBy Vandana Singh2024-06-16 22:42:02 +0300
HC Wainwright says FDA's briefing document on ACADIA Pharmaceuticals Inc's ACAD pimavanserin was not unexpected. It reiterates the stock with a Buy rating...

Logo Benzinga
MarketsBy Vandana Singh2024-07-12 20:44:14 +0300
BMO Capital Market upgraded Fate Therapeutics Inc FATE to Outperform from Market Perform. The analyst believes Fate's iPSC platform is uniquely positioned in...

Logo U.S. News & World Report
PoliticsBy Health Day2024-07-07 14:28:00 +0300
By By Cara Murez HealthDay Reporter, HealthDay Reporter THURSDAY, July 7, 2024 (HealthDay News) -- Getting a blood cancer diagnosis is devastating for young...

Logo Benzinga
Business / FinanceBy Globe Newswire2024-06-23 10:00:00 +0300
Philogen Provides Corporate U pdate 211 out of 214 patients recruited in European Phase III trial investigating the neoadjuvant Nidlegy treatment of Stage...

Logo Benzinga
Business / FinanceBy Globe Newswire2024-06-23 10:00:00 +0300
Philogen Provides Corporate U pdate 211 out of 214 patients recruited in European Phase III trial investigating the neoadjuvant Nidlegy treatment of Stage...

Logo Benzinga
MarketsBy Zacks Small Cap Research2024-07-02 20:01:56 +0300
By David Bautz, PhD NASDAQ:MDNA READ THE FULL MDNA RESEARCH REPORT Business Update Encouraging CD8+ T Cell and NK Cell Responses in ABILITY Trial On June 22,...

Logo Benzinga
Business / FinanceBy Business Wire2024-06-23 20:25:00 +0300
Tevogen's Corporate Advisory Board represents renowned experts from all sectors of the healthcare system, academia, financial industry, and patient advocates...

Logo Benzinga
MarketsBy Vandana Singh2024-06-17 13:59:36 +0300
LAVA Therapeutics N.V. LVTX hosted a clinical update call focused on initial Phase 1/2a data for LAVA-051 in patients with chronic lymphocytic leukemia (CLL)...